A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1202 in Patients With Advanced Solid Tumors
Latest Information Update: 30 Apr 2024
At a glance
- Drugs BA 1202 (Primary)
- Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shandong Boan Biotechnology
Most Recent Events
- 24 Apr 2024 Status changed from not yet recruiting to recruiting.
- 20 Jun 2023 New trial record